NCT00487708 - Safety, Efficacy, Pharmacokinetics, Pharmacodynamics of ACZ885 in Patients With NALP3 Mutations and Clinical Symptoms | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions

NALP3 Mutation

Interventions

DRUG

canakinumab

Trial Locations (10)

Novartis Investigator Site, Lille

Novartis Investigator Site, Berlin

Novartis Investigator Site, Dresden

Novartis Investigator Site, Heidelberg

Novartis Investigator Site, Marburg

Novartis investigative site, Nuremberg

Novartis Investigator Site, Tübingen

Novartis Investigator Site, New Dehli

Novartis Investigator Site, Oviedo

Novartis Investigative site, London